Engineered biosynthesis of gilvocarcin analogues with altered deoxyhexopyranose moieties

Applied and Environmental Microbiology

Volumn 77, Issue 2, 2011, Pages 435-441

  Shepherd, Micah D ^a   Liu, Tao ^a,c   Méndez, Carmen ^b   Salas, Jose A ^b   Rohr, Jürgen ^a  

^a University of Kentucky   (United States)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c SelectX Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGUCYCLINONE; ANTI-TUMOR ACTIVITIES; BREAST CANCER; CELL LINES; COMPLEMENTATION; DEOXYSUGAR; DONOR SUBSTRATES; ENGINEERED BIOSYNTHESIS; GILVOCARCINS; GLYCOSYL TRANSFERASE; HUMAN LUNG; LUNG CANCER; NATURAL SUGARS; STREPTOMYCES LIVIDANS;

BIOCHEMISTRY; BIOLOGICAL ORGANS; CELL CULTURE; DISEASES; SUGARS;

BIOSYNTHESIS;

2,4 DIDEOXYHEXOPYRANOSE; 2,4-DIDEOXYHEXOPYRANOSE; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; COUMARIN; COUMARIN DERIVATIVE; DEOXYSUGAR;

BIOASSAY; BIOENGINEERING; CANCER; PLASMID; SUBSTRATE; SUGAR;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE; STREPTOMYCES LIVIDANS; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOSYNTHETIC PATHWAYS; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DEOXY SUGARS; HUMANS; MICE; STREPTOMYCES LIVIDANS;

MURINAE; STREPTOMYCES LIVIDANS;

EID: 79551474367     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01774-10     Document Type: Article

References (45)

1. Alegria, A. E., L. Zayas, and N. Guevara. 1995. A comparative study of the visible light photochemistry of gilvocarcins V and M. Photochem. Photobiol. 62:409-415.
2. Antczak, A., T. Tsubota, P. Kaufman, and J. Berger. 2006. Structure of the yeast histone H3-ASF1 interaction: Implications for chaperone mechanism, species-specific interactions, and epigenetics. BMC Struct. Biol. 6:26.
3. Arce, R., R. Oyola, and A. E. Alegria. 1998. The photobiological differences of gilvocarcins V and M are not related to their transient intermediates and triplet yields. Photochem. Photobiol. 68:25-31.
4. Baig, I., M. Pérez, A. F. Braña, R. Gomathinayagam, C. Damodaran, J. A. Salas, C. Méndez, and J. Rohr. 2008. Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity. J. Nat. Prod. 71:199-207.
5. Balitz, D. M., F. A. O'Herron, J. Bush, D. M. Vyas, D. E. Nettleton, R. E. Grulich, W. T. Bradner, T. W. Doyle, E. Arnold, and J. Clardy. 1981. Antitumor agents from Streptomyces anandii: Gilvocarcins V, M and E. J. Antibiot. 34:1544-1555.
6. Campbell, J. A., G. J. Davies, V. Bulone, and B. Henrissat. 1997. A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities. Biochem. J. 326:929-939. (Erratum, 329:719.)
7. Coutinho, P. M., E. Deleury, G. J. Davies, and B. Henrissat. 2003. An evolving hierarchical family classification for glycosyltransferases. J. Mol. Biol. 328:307-317.
8. Eickbush, T. H., and E. N. Moudrianakis. 1978. The histone core complex: An octamer assembled by two sets of protein-protein interactions. Biochemistry 17:4955-4964.
9. Elespuru, R. K., and S. K. Gonda. 1984. Activation of antitumor agent gilvocarcins by visible light. Science 223:69-71.
10. Fischer, C., F. Lipata, and J. Rohr. 2003. The complete gene cluster of the antitumor agent gilvocarcin V and its implication for the biosynthesis of the gilvocarcins. J. Am. Chem. Soc. 125:7818-7819.
11. Kharel, M. K., S. E. Nybo, M. D. Shepherd, and J. Rohr. 2010. Cloning and characterization of the ravidomycin and chrysomycin biosynthetic gene clusters. Chembiochem 11:523-532.
12. Kharel, M. K., P. Pahari, H. Lian, and J. Rohr. 2009. GilR, an unusual lactone-forming enzyme involved in gilvocarcin biosynthesis. Chembiochem 10:1305-1308.
13. Kieser, T., M. J. Bibb, M. J. Buttner, K. F. Chater, and D. A. Hopwood. 2000. Practical streptomyces genetics. The John Innes Foundation, Norwich, United Kingdom.
14. Knobler, R. M., F. B. Radlwimmer, and M. J. Lane. 1992. Gilvocarcin V exhibits both equilibrium DNA binding and UV light induced DNA adduct formation which is sequence context dependent. Nucleic Acids Res. 20: 4553-4557.
15. Kojiri, K., H. Arakawa, F. Satoh, K. Kawamura, A. Okura, H. Suda, and M. Okanishi. 1991. New antitumor substances, BE-12406A and BE-12406B, produced by a streptomycete. I. Taxonomy, fermentation, isolation, physicochemical and biological properties. J. Antibiot. (Tokyo) 44:1054-1060.
16. Li, Y. Q., X. S. Huang, K. Ishida, A. Maier, G. Kelter, Y. Jiang, G. Peschel, K. D. Menzel, M. G. Li, M. L. Wen, L. H. Xu, S. Grabley, H. H. Fiebig, C. L. Jiang, C. Hertweck, and I. Sattler. 2008. Plasticity in gilvocarcin-type Cglycoside pathways: Discovery and antitumoral evaluation of polycarcin V from Streptomyces polyformus. Org. Biomol. Chem. 6:3601-3605.
17. Liu, T., M. K. Kharel, C. Fischer, A. McCormick, and J. Rohr. 2006. Inactivation of gilGT, encoding a C-glycosyltransferase, and gilOIII, encoding a P450 enzyme, allows the details of the late biosynthetic pathway to gilvocarcin V to be delineated. Chembiochem 7:1070-1077.
18. Liu, T., M. K. Kharel, L. Zhu, S. A. Bright, C. Mattingly, V. R. Adams, and J. Rohr. 2009. Inactivation of the ketoreductase gilU gene of the gilvocarcin biosynthetic gene cluster yields new analogues with partly improved biological activity. Chembiochem 10:278-286.
19. Lombó, F., M. Gibson, L. Greenwell, A. F. Braña, J. Rohr, J. A. Salas, and C. Méndez. 2004. Engineering biosynthetic pathways for deoxysugars: Branched-chain sugar pathways and derivatives from the antitumor tetracenomycin. Chem. Biol. 11:1709-1718.
20. Luzhetskyy, A., and A. Bechthold. 2008. Features and applications of bacterial glycosyltransferases: Current state and prospects. Appl. Microbiol. Biotechnol. 80:945-952.
21. MacNeil, D. J., K. M. Gewain, C. L. Ruby, G. Dezeny, P. H. Gibbons, and T. MacNeil. 1992. Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration vector. Gene 111:61-68.
22. Matsumoto, A., Y. Fujiwara, R. K. Elespuru, and P. C. Hanawalt. 1994. Photoactivated gilvocarcin V induces DNA-protein crosslinking in genes for human ribosomal RNA and dihydrofolate reductase. Photochem. Photobiol. 60:225-230.
23. Matsumoto, A., and P. C. Hanawalt. 2000. Histone H3 and heat shock protein GRP78 are selectively cross-linked to DNA by photoactivated gilvocarcin V in human fibroblasts. Cancer Res. 60:3921-3926.
24. McGee, L. R., and R. Misra. 1990. Gilvocarcin photobiology. Isolation and characterization of the DNA photoadduct. J. Am. Chem. Soc. 112:2386-2389.
25. Nakajima, S., K. Kojiri, H. Suda, and M. Okanishi. 1991. New antitumor substances, BE-12406A and BE-12406B, produced by a streptomycete. II. Structure determination. J. Antibiot. (Tokyo) 44:1061-1064.
26. Nakano, H., Y. Matsuda, K. Ito, S. Ohkubo, M. Morimoto, and F. Tomita. 1981. Gilvocarcins, new antitumor antibiotics. 1. Taxonomy, fermentation, isolation, and biological activities. J. Antibiot. 34:266-270.
27. Nakashima, T., T. Fujii, K. Sakai, S. Tomohiro, H. Kumagai, and T. Yoshioka. February 2000. Chrysomycin derivative compounds and use as antitumor agents. U.S. patent 6,030,951.
28. Olano, C., M. S. Abdelfattah, S. Gullón, A. F. Braña, J. Rohr, C. Méndez, and J. A. Salas. 2008. Glycosylated derivatives of steffimycin: Insights into the role of the sugar moieties for the biological activity. Chembiochem 9:624-633.
29. Paget, M. S., L. Chamberlin, A. Atrih, S. J. Foster, and M. J. Buttner. 1999. Evidence that the extracytoplasmic function sigma factor-E is required for normal cell wall structure in Streptomyces coelicolor A3(2). J. Bacteriol. 181:204-211.
30. Peak, M. J., J. G. Peak, C. M. Blaumueller, and R. K. Elespuru. 1988. Photosensitized DNA breaks and DNA-to-protein crosslinks induced in human cells by antitumor agent gilvocarcin V. Chem. Biol. Interact. 67:267-274.
31. Pérez, M., F. Lombó, I. Baig, A. F. Braña, J. Rohr, J. A. Salas, and C. Méndez. 2006. Combinatorial biosynthesis of antitumor deoxysugar pathways in Streptomyces griseus: Reconstitution of "unnatural natural gene clus-ters" for the biosynthesis of four 2,6-D-dideoxyhexoses. Appl. Environ. Microbiol. 72:6644-6652.
32. Rodriguez, L., I. Aguirrezabalaga, N. Allende, A. F. Braña, C. Méndez, and J. A. Salas. 2002. Engineering deoxysugar biosynthetic pathways from antibiotic- producing microorganisms: A tool to produce novel glycosylated bioactive compounds. Chem. Biol. 9:721-729.
33. Rodriguez, L., C. Oelkers, I. Aguirrezabalaga, A. F. Braña, J. Rohr, C. Méndez, and J. A. Salas. 2000. Generation of hybrid elloramycin analogs by combinatorial biosynthesis using genes from anthracycline-type and macrolide biosynthetic pathways. J. Mol. Microbiol. Biotechnol. 2:271-276.
34. Rubinstein, L. V., R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. A. Scudiero, A. Monks, and M. R. Boyd. 1990. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1113-1118.
35. Salas, A. P., L. Zhu, C. Sanchez, A. F. Brana, J. Rohr, C. Mendez, and J. A. Salas. 2005. Deciphering the late steps in the biosynthesis of the anti-tumour indolocarbazole staurosporine: Sugar donor substrate flexibility of the StaG glycosyltransferase. Mol. Microbiol. 58:17-27.
36. Salas, J. A., and C. Mendez. 2009. Indolocarbazole antitumour compounds by combinatorial biosynthesis. Curr. Opin. Chem. Biol. 13:152-160.
37. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: A laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
38. Sehgal, S. N., H. Czerkawski, A. Kudelski, K. Pandev, R. Saucier, and C. Vezina. 1983. Ravidomycin (AY-25,545), a new antitumor antibiotic. J. Antibiot. 35:355-361.
39. Shepherd, M. D., M. K. Kharel, L. L. Zhu, S. G. Van Lanen, and J. Rohr. 2010. Delineating the earliest steps of gilvocarcin biosynthesis: Role of GilP and GilQ in starter unit specificity. Org. Biomol. Chem. 8:3851-3856.
40. Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82: 1107-1112.
41. Takahashi, K., M. Yoshida, F. Tomita, and K. Shirahata. 1981. Gilvocarcins, new antitumor antibiotics. 2. Structural elucidation. J. Antibiot. 34:271-275.
42. Thibodeaux, C. J., C. E. Melancon III, and H. W. Liu. 2008. Natural-product sugar biosynthesis and enzymatic glycodiversification. Angew. Chem. Int. Ed. Engl. 47:9814-9859.
43. Weiss, U., K. Yoshihira, R. J. Highet, R. J. White, and T. T. Wei. 1982. The chemistry of the antibiotics chrysomycin A and B. Antitumor activity of chrysomycin A. J. Antibiot. 35:1194-1201.
44. Williams, G. J., R. Gantt, and J. S. Thorson. 2008. The impact of enzyme engineering upon natural product glycodiversification. Curr. Opin. Chem. Biol. 12:556-564.
45. Yamashita, N., K. Shin-ya, K. Furihata, Y. Hayakawa, and H. Seto. 1998. New ravidomycin analogues, FE35A and FE35B, apoptosis inducers produced by Streptomyces rochei. J. Antibiot. 51:1105-1108.